196 related articles for article (PubMed ID: 16863656)
1. Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits.
Quesada L; Sevcik C; Lomonte B; Rojas E; Gutiérrez JM
Toxicon; 2006 Sep; 48(3):255-63. PubMed ID: 16863656
[TBL] [Abstract][Full Text] [Related]
2. Detection of venom-antivenom (VAV) immunocomplexes in vitro as a measure of antivenom efficacy.
O'Leary MA; Isbister GK
Toxicon; 2014 Jan; 77():125-32. PubMed ID: 24252422
[TBL] [Abstract][Full Text] [Related]
3. Intravenous administration of equine-derived whole IgG antivenom does not induce early adverse reactions in non-envenomed horses and cows.
Estrada R; Herrera M; Segura A; Araya J; Boschini C; Gutiérrez JM; León G
Biologicals; 2010 Nov; 38(6):664-9. PubMed ID: 20833066
[TBL] [Abstract][Full Text] [Related]
4. Absorption and elimination of viper venom after antivenom administration.
Rivière G; Choumet V; Saliou B; Debray M; Bon C
J Pharmacol Exp Ther; 1998 May; 285(2):490-5. PubMed ID: 9580588
[TBL] [Abstract][Full Text] [Related]
5. Comparison between IgG and F(ab')(2) polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions.
León G; Monge M; Rojas E; Lomonte B; Gutiérrez JM
Toxicon; 2001 Jun; 39(6):793-801. PubMed ID: 11137538
[TBL] [Abstract][Full Text] [Related]
6. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy.
Rivière G; Choumet V; Audebert F; Sabouraud A; Debray M; Scherrmann JM; Bon C
J Pharmacol Exp Ther; 1997 Apr; 281(1):1-8. PubMed ID: 9103473
[TBL] [Abstract][Full Text] [Related]
7. Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration.
León G; Segura A; Herrera M; Otero R; França FO; Barbaro KC; Cardoso JL; Wen FH; de Medeiros CR; Prado JC; Malaque CM; Lomonte B; Gutiérrez JM
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1115-9. PubMed ID: 18561967
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom.
Segura A; León G; Su CY; Gutiérrez JM; Burnouf T
Biologicals; 2009 Oct; 37(5):306-12. PubMed ID: 19540775
[TBL] [Abstract][Full Text] [Related]
9. Effect of premedication with subcutaneous adrenaline on the pharmacokinetics and immunogenicity of equine whole IgG antivenom in a rabbit model.
Herrera M; Sánchez M; Machado A; Ramírez N; Vargas M; Villalta M; Sánchez A; Segura Á; Gómez A; Solano G; Gutiérrez JM; León G
Biomed Pharmacother; 2017 Jun; 90():740-743. PubMed ID: 28419970
[TBL] [Abstract][Full Text] [Related]
10. Role of the animal model on the pharmacokinetics of equine-derived antivenoms.
Rojas A; Vargas M; Ramírez N; Estrada R; Segura A; Herrera M; Villalta M; Gómez A; Gutiérrez JM; León G
Toxicon; 2013 Aug; 70():9-14. PubMed ID: 23557996
[TBL] [Abstract][Full Text] [Related]
11. Antivenom cross neutralisation in a suspected Asian pit viper envenoming causing severe coagulopathy.
Isbister GK; Maduwage K; Page CB
Toxicon; 2014 Nov; 90():286-90. PubMed ID: 25178876
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of four Peruvian Bothrops sp. snake venoms by polyvalent antivenoms produced in Perú and Costa Rica: preclinical assessment.
Rojas E; Quesada L; Arce V; Lomonte B; Rojas G; Gutiérrez JM
Acta Trop; 2005 Jan; 93(1):85-95. PubMed ID: 15589801
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics and multiepitope DNA immunization to design rational snake antivenom.
Wagstaff SC; Laing GD; Theakston RD; Papaspyridis C; Harrison RA
PLoS Med; 2006 Jun; 3(6):e184. PubMed ID: 16737347
[TBL] [Abstract][Full Text] [Related]
14. Analysis of camelid IgG for antivenom development: Immunoreactivity and preclinical neutralisation of venom-induced pathology by IgG subclasses, and the effect of heat treatment.
Cook DA; Samarasekara CL; Wagstaff SC; Kinne J; Wernery U; Harrison RA
Toxicon; 2010 Sep; 56(4):596-603. PubMed ID: 20547172
[TBL] [Abstract][Full Text] [Related]
15. Use of irradiated elapid and viperid venoms for antivenom production in small and large animals.
de la Rosa G; Olvera F; Cruz E; Paniagua D; Corzo G
Toxicon; 2018 Dec; 155():32-37. PubMed ID: 30315836
[TBL] [Abstract][Full Text] [Related]
16. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa.
Gutiérrez JM; Rojas E; Quesada L; León G; Núñez J; Laing GD; Sasa M; Renjifo JM; Nasidi A; Warrell DA; Theakston RD; Rojas G
Trans R Soc Trop Med Hyg; 2005 Jun; 99(6):468-75. PubMed ID: 15837359
[TBL] [Abstract][Full Text] [Related]
17. Assessment of quality, safety, and pre-clinical toxicity of an equine polyvalent anti-snake venom (Pan Africa): Determination of immunological cross-reactivity of antivenom against venom samples of Elapidae and Viperidae snakes of Africa.
Patra A; Kalita B; Mukherjee AK
Toxicon; 2018 Oct; 153():120-127. PubMed ID: 30189243
[TBL] [Abstract][Full Text] [Related]
18. Preparation of a novel antivenom against Atractaspis and Walterinnesia venoms.
Ismail M; Al-Ahaidib MS; Abdoon N; Abd-Elsalam MA
Toxicon; 2007 Jan; 49(1):8-18. PubMed ID: 17097125
[TBL] [Abstract][Full Text] [Related]
19. Development of a chicken-derived antivenom against the taipan snake (Oxyuranus scutellatus) venom and comparison with an equine antivenom.
Navarro D; Vargas M; Herrera M; Segura Á; Gómez A; Villalta M; Ramírez N; Williams D; Gutiérrez JM; León G
Toxicon; 2016 Sep; 120():1-8. PubMed ID: 27373994
[TBL] [Abstract][Full Text] [Related]
20. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies.
Seifert SA; Boyer LV
Ann Emerg Med; 2001 Feb; 37(2):189-95. PubMed ID: 11174238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
